Profund Advisors’s Zevra Therapeutics ZVRA Stock Holding History

Profund Advisors’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.2M	Buy	109,547 +94,021	+606%	+$1.11M	0.03%	319
2026 Q2	$223K	Buy	15,526 +1,780	+13%	+$19.8K	0.01%	1016
2026 Q1	$128K	Sell	13,746 -4,332	-24%	-$39K	﹤0.01%	1061
2025 Q4	$162K	Buy	18,078 +888	+5%	+$8.4K	﹤0.01%	1200
2025 Q3	$163K	Buy	+17,190	New	+$172K	0.01%	1009
2025 Q1	–	Sell	-12,055	Closed	-$101K	–	1119
2024 Q4	$101K	Buy	+12,055	New	+$103K	﹤0.01%	1068

Other funds holding ZVRA

Integrity Alliance Urbandale, Iowa $3.28B AUM 15.79% 1-Year Est. Return

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

Retirement Planning Company of New England Warwick, Rhode Island $263M AUM 26.23% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

MAM

Mystic Asset Management Warwick, Rhode Island $451M AUM 22.13% 1-Year Est. Return

Inspire Investing Meridian, Idaho $2.37B AUM 29.82% 1-Year Est. Return

IFG Advisors St. Louis, Missouri $730M AUM 19.37% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Quaker Wealth Management Moorestown, New Jersey $341M AUM 9.06% 1-Year Est. Return

Profund Advisors's ZVRA Position: Q3 2026 in Review

Profund Advisors increased its Zevra Therapeutics (ZVRA) stake by 606% in Q3 2026, buying an estimated $1.11M and bringing the position to 109,547 shares worth $1.2M. The position accounts for 0.03% of the portfolio, ranked #319.

Profund Advisors first reported a position in ZVRA in Q4 2024 and has held it in 6 quarters since. 35 funds tracked by Wall St. Rank hold ZVRA as of Q3 2026.

Profund Advisors held 109,547 shares of Zevra Therapeutics worth $1.2M as of Q3 2026.
Profund Advisors bought 94,021 Zevra Therapeutics shares in Q3 2026, an estimated $1.11M.
Zevra Therapeutics made up 0.03% of Profund Advisors's portfolio in Q3 2026, its #319 holding.
Profund Advisors first reported a position in Zevra Therapeutics in Q4 2024 and has held it in 6 quarters since.
35 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q3 2026.

Based on Profund Advisors's 13F filing for Q3 2026, filed 29 Oct 2026.